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&p.1:Abstract In stratified squamous epithelia a critical bal-
ance among cell proliferation, differentiation, and death
must be maintained in order for these tissues to fulfill
their barrier function. Previous studies have demonstrat-
ed that plasminogen activator inhibitor 2 (PAI-2) is a
product of differentiating epidermal keratinocytes, sug-
gesting a role for this inhibitor during squamous differ-
entiation. Furthermore, in certain tumor cell lines, over-
expression of PAI-2 confers resistance to the induction
of programmed cell death, suggesting cytoprotective
function(s). In the present study we demonstrate that
PAI-2 mRNA and protein are constitutively and unique-
ly expressed in differentiating cells of murine stratified
squamous epithelia, including epidermis, esophagus, va-
gina, oral mucosa, and tongue. PAI-2 immunohisto-
chemical localization patterns suggest a predominantly
cytosolic distribution, consistent with biochemical iden-
tification of the major PAI-2 species as a 43-kDa, pre-
sumably non-glycosylated protein. Functional analysis
shows that the majority of epithelial PAI-2 is active. In
contrast to the high levels of PAI-2 expression in strati-
fied squamous epithelia, little or no PAI-2 is detectable
in simple epithelia. These findings suggest that epithe-
lial PAI-2 may mediate inhibition of intracellular pro-
teinases associated with events during terminal differen-
tiation and death that are unique to stratified squamous
epithelia.&bdy:
Introduction
Stratified squamous epithelia are self-renewing tissues
consisting of multiple layers of keratinocytes that line
body surfaces and are designed to protect the organism
from physical, chemical or microbial perturbations. To
fulfill their vital barrier function, stratified squamous
epithelia must maintain a dynamic balance among prolif-
eration, terminal differentiation, and death. The prolifer-
ative keratinocyte population is located primarily in the
basal layer residing along the basement membrane; the
superficial layers are comprised of postmitotic, increas-
ingly differentiated cells. Terminal differentiation culmi-
n tes with the death of the keratinocyte and its conver-
sion into a keratin filament–matrix complex encased by a
thickened proteinaceous membrane formed via the cross-
linking action of transglutaminase. These terminally dif-
ferentiated cells, which are continuously shed from the
epithelial surface, constitute a central aspect of the pro-
tective function of stratified squamous epithelia (Green
1977, 1980; Eckert and Rorke 1989).
Terminal differentiation in stratified squamous epithe-
lia may be thought of as a high specialized form of
programmed cell death, in which the postmitotic kerati-
nocyte must follow an elaborate series of changes in
gene and protein expression prior to nuclear disintegra-
tion, protein cross-linking, and death (Fesus et al. 1991;
Gavrieli et al. 1992; Polakowska and Haake 1994; Tam-
ada et al. 1994; Metcalfe and Streuli 1997). Intracellular
proteinases have been implicated both in programmed
cell death and terminal differentiation. An increasingly
large family of intracellular proteinases promotes pro-
grammed cell death through cleavage of cytoplasmic
and/or nuclear targets (Ashkenas and Werb 1996). Fur-
thermore, numerous proteins are degraded during the
conversion of a keratinocyte to a terminally differentiat-
ed, dead cell; thus proteolytic enzymes must be active
during the last stages of differentiation (Green 1977,
1980; Eckert and Rorke 1989; Resing et al. 1993). Nu-
merous proteinase inhibitors have evolved which regu-
late proteinases and thus may prevent damage to cells
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and tissues. One such proteinase inhibitor, which we
have previously suggested may be involved in the regula-
tion of keratinocyte differentiation, is plasminogen acti-
vator inhibitor type 2 (PAI-2; Lyons-Giordano et al.
1994; Jensen et al. 1995; Wang and Jensen 1998). A re-
cent survey of mouse organs revealed that the highest
level of this inhibitor is in epidermal keratinocytes (Kaw-
ata et al. 1996), consistent with the observations that
PAI-2 mRNA, antigen, and activity are readily detectable
in human epidermis in vivo (Hibino et al. 1988; Lyons-
Giordano et al. 1994).
As a type of serine proteinase inhibitor (serpin), PAI-2
is unusual in that it lacks a hydrophobic signal sequence
and thus a significant fraction is retained within the cyto-
plasm (Ye et al. 1988; Belin et al. 1989). PAI-2 is found
in two forms, non-glycosylated and glycosylated. In
macrophages, the latter is found in the conditioned medi-
um (Wohlwend et al. 1987a, b) but in cultured human ke-
ratinocytes both forms remain cell associated (Wang and
Jensen 1998). Only very few other proteins (e.g., yeast
invertase, mammalian gelsolin) have been found simulta-
neously in cytoplasmic and secreted forms (Belin et al.
1989). The simultaneous presence of cytosolic and se-
creted PAI-2 suggests potentially distinct functions of
the two forms.
As reflected by its name, the only known proteolytic
enzyme targets for PAI-2 are urokinase-type plasmino-
gen activator (uPA) and tissue-type plasminogen activa-
tor (tPA) (Andreasen et al. 1990; Kruithof et al. 1995).
Both PAs convert plasminogen to its active form, plas-
min, which acts in the extracellular space to cleave a
number of substrates, including fibrin, other extracellular
matrix molecules, and procollagenase (Danø et al. 1985).
There is good evidence to support the involvement of the
PA cascade in numerous physiological and pathological
processes, e.g., vascular patency, cell migration, inflam-
mation, neuronal degeneration, and tumor invasion
(Carmeliet and Collen 1995; Rømer et al. 1996; Andrea-
sen et al. 1997; Tsirka et al. 1997). Although most of the
actions of uPA and tPA are mediated via cleavage of
plasminogen, other substrates have been proposed (e.g.,
hepatocyte growth factor, fibronectin; Quigley et al.
1987; Naldini et al. 1992; Mars et al. 1993); however,
consistent with the fact that the PAs are secreted en-
zymes, their proposed substrates are all extracellular.
The secreted form of PAI-2 is likely to regulate PA activ-
ity, particularly uPA, which it inhibits more efficiently
than tPA (Andreasen et al. 1990). However, given that a
substantial fraction of PAI-2 remains in the cytosol of
cells synthesizing this inhibitor, the possibility of a plas-
minogen activator-independent, intracellular role appears
reasonable. Several studies have indeed provided evi-
dence for this point of view. Overexpression of PAI-2 in
the cytoplasm of fibrosarcoma or epithelial cell lines has
been shown to confer resistance to the induction of pro-
grammed cell death (Kumar and Baglioni 1991; Dickin-
son 1995). Active intracellular PAI-2 was required for
this function, but its inhibitory activity was not directed
against uPA (Dickinson et al. 1995, 1998). These data
have led to the hypothesis that PAI-2 may exert cytopro-
tective functions, independent of uPA inhibition, in a va-
riety of cell types.
We have previously postulated that such a cytoprotec-
tiv  function of PAI-2 may extend to normal epidermis.
In human epidermis, PAI-2 mRNA and protein have
been localized predominantly to superficial layers
(Hibino et al. 1988; Lyons-Giordano et al. 1994), indi-
cating that PAI-2 is a product of differentiated keratino-
cytes. Consistent with these in vivo data, more differenti-
ated keratinocyte cultures have relatively greater levels
of PAI-2 (Wang and Jensen 1998). Thus PAI-2 is appro-
priately placed to protect differentiating epidermal kera-
tinocytes from premature action of cytoplasmic protein-
ases that may contribute to their terminal differentiation,
dissolution, and eventual death. To consider this hypoth-
esis further, we have characterized PAI-2 using biochem-
ical, immunohistochemical, and/or in situ hybridization
approaches in a variety of murine epithelia. We reasoned
that determination and comparison of PAI-2 expression
patterns and properties within different types of epithelia
would suggest the physiological circumstances under
which PAI-2 normally functions. Our data indicate that
PAI-2 is uniquely expressed by stratified squamous epi-
thelia, in which its properties are consistent with a pro-
tective role during terminal differentiation.
Materials and methods
Mice
For immunohistochemical staining and in situ hybridization, skin
biopsies were collected from C57BL/6, C57BL/6 – 129 hybrid,
and Sencar strains at different ages of life. Our results showed no
strain-related differences in PAI-2 expression patterns. Biochemi-
cal and functional analysis of epidermal extracts were conducted
using C57BL/6 mice. Mice were euthanized in CO2.
Tissue preparation
Skin biopsies were collected from the nape of the neck unless
specified otherwise. Tissues for immunohistochemical staining
and in situ hybridization were fixed overnight in 4% paraformal-
dehyde/Dulbecco’s phosphate-buffered saline (PBS; Life Technol-
ogies, Grand Island, N.Y., USA), incubated in 80% ethanol for 24
h, and paraffin embedded. Sections (5 µm) were prepared on Su-
perfrost Plus glass slides (Fisher Scientific, Pittsburg, PA., USA).
Immunohistochemical staining
Polyclonal antiserum against mouse PAI-2 was prepared in rabbit
by injection with a mouse PAI-2:GST fusion protein that had been
purified from inclusion bodies by 8-M urea extraction and gluta-
thione–Sepharose chromatography. The antiserum was adsorbed
with sham-transfected bacterial lysates to remove any cross-reac-
tivity with either bacterial or GST antigens. Rabbit anti-mouse
PAI-2 IgG was purified using an ImmunoPure (A) IgG Purifica-
ti n kit (Pierce, Rockford, IL., USA). Immunohistochemical stain-
ing was performed using a Vectastain ABC (avidin–biotin–peroxi-
dase complex) kit (Vector Laboratories, Burlingame, CA., USA).
Paraffin sections were briefly heated to 55° C, deparaffinized in
xylene for 3×5 min, rehydrated through a graded ethanol series,
and fixed in 4% paraformaldehyde/PBS. After rinsing in PBS,
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non-specific binding was blocked in 10% normal goat serum in
PBS. Sections were incubated with rabbit anti-mouse PAI-2 IgG
(5 µg/ml) overnight at 4° C. Sections were washed 3×10 min in
PBS, then incubated with biotinylated goat anti-rabbit IgG (7.5
µg/ml) 1 h at room temperature. Following washes in PBS, sec-
tions were incubated with the avidin–biotin–peroxidase complex
according to the manufacturer’s recommendation. Detection of an-
tibody binding was conducted using the substrate 3,3′-diamino-
benzidine (Sigma, St. Louis, MO., USA). Control experiments
were performed using normal rabbit IgG.
In situ hybridization
In situ hybridization for mouse PAI-2 mRNA was performed ac-
cording to procedures published previously (Keeton et al. 1993;
Jensen and Lavker 1996). A 930-bp PstI-PvuII fragment of the
mouse PAI-2 cDNA (kindly provided by D. Belin) was subcloned
into pBluescript SK+/− (Stratagene, La Jolla, CA., USA) at the
EcoRI-HindIII site. Digestion with HindIII and transcription with
T3 RNA polymerase were used for antisense probes, and digestion
with SmaI and transcription with T7 RNA polymerase were used
for sense probes. [35S]-labeled RNA probes were transcribed using
a Riboprobe RNA Labelling kit (Promega Corporation, Madison,
WI., USA).
Epidermal extraction
The entire trunk skin was removed and immersed in 0.15 M NaCl
for 1 min at 56° C to separate the epidermis from the underlying
dermis. Epidermis was homogenized on ice in 0.01 M sodium
phosphate pH 7.0 (ca. 10 µl per mg wet weight) and extracted for
30 min at 4° C. After centrifugation (ca. 7000 xg for 10 min), the
supernatant (low-salt extract) was collected. The remaining pellet
was then resuspended in an equal volume of 2 M KSCN/0.1% Tri-
ton X-100 and reextracted for 30 min at 4° C followed by centrifu-
gation. Supernatant (high-salt extract) was collected and dialyzed
against 0.01 M sodium phosphate, pH 7.0. All samples were stored
at −70° C. Using this extraction procedure, PA inhibitors can be de-
tected in the low-salt extract whereas PA enzymes are present in
the high-salt extract, as we previously found for human epidermis
(Lyons-Giordano et al. 1994). Determination of total extracted pro-
tein was performed using a BCA Protein Assay kit (Pierce).
Western blot
Samples were electrophoresed in a 9.5% polyacrylamide gel in the
presence of SDS prior to electroblot transfer onto PVDF mem-
brane (Immobilon P; Millipore, Bedford, MA., USA). Non-specif-
ic antibody binding was blocked in 1% bovine serum albumin
(Catalog number A-4378, Sigma) in TRIS-buffered saline (TBS;
20 mM TRIS base, 137 mM NaCl, pH 7.6) containing 0.2%
Tween-20. Immunodetection was conducted by incubation with
rabbit anti-mouse PAI-2 IgG (1.5 µg/ml) for 1 h at room tempera-
ture. Blots were washed in TBS/1% Tween-20 and incubated with
horseradish peroxidase-labelled goat anti-rabbit IgG (1:1000 dilu-
tion: Boehringer Mannheim Biochemicals, Indianapolis, IN.,
USA) for 1 h at room temperature. Following washes in TBS/1%
Tween-20, antibody binding was detected using an ECL kit
(Amersham Life Science, Arlington Heights, IL., USA). Control
experiments were performed using normal rabbit IgG.
Functional activity of epidermal PAI-2 was assessed by prein-
cubation prior to electrophoresis of epidermal extracts (15 µg total
protein) with 50 ng 33-kDa human uPA (Mochida Pharmaceuti-
cals, Tokyo, Japan) for 10 min on ice.
uPa inhibitory assay immunoprecipitation
PA inhibitory activity was assessed using a kinetic assay which
measures the inhibition of uPA-mediated cleavage of the chromo-
genic substrate S-2444 (Chromogenix, Mölndal, Sweden). All as-
says were performed in 96-well plates in a final volume of 110 µl.
Epidermal extracts were incubated in the presence of standard uPA
(25 Plough U/ml; Leo Pharmaceutical Products, Ballerup, Den-
mark), 1 h at room temperature, to allow formation of uPA:PA in-
hibitor complexes. The optical density at 405 nm (OD405) was
measured prior to substrate addition, and then with time after addi-
tion of 0.3 mM S-2444. OD405 readings were normalized by sub-
raction of background readings and compared to a standard curve
obtained with 25 Plough U/ml standard uPA alone.
In some experiments, prior to the inhibitory assay, PAI-2 was
immunoprecipitated from epidermal extracts using rabbit anti-
mouse PAI-2 IgG (see above) or rabbit anti-mouse PAI-1 IgG
(kindly donated by D. Loskutoff). Protein G Plus/protein A – aga-
rose beads (Oncogene Reseach, Cambridge, MA., USA) were pre-
treated by washes in NET buffer (0.5 M NaCl, 1 mM EDTA, 50
mM TRIS-HCl, pH 8.1) containing 0.5% and then 0.05% Nonidet
P-40 (NP-40; Sigma). To reduce non-specific binding, beads were
incubated in 0.2% hemoglobin in NET/0.05% NP-40, 1 h at 4° C,
and in 2% immunoglobulin-free BSA (Sigma) in NET/0.05% NP-
40, overnight at 4° C. For immunoprecipitation, low-salt epider-
mal extracts (50 µl containing ca 85 µg total extracted protein)
were incubated with 100 µl Protein G Plus/protein A – agarose
beads and 20 µg rabbit anti-mouse PAI-2 IgG overnight at 4° C.
Control experiments were performed by addition of normal rabbit
IgG or by omitting additions of antibody and beads. Agarose
beads were pelleted and supernatants were assayed for uPA inhibi-
tory activity as described above.
Results
The pattern of PAI-2 expression changes
during murine epidermal development
During the first 2 weeks of life, mouse epidermis under-
goes characteristic morphological changes. Late gestatio-
nal and neonatal mouse epidermis can be considered in a
‘hyperproliferative’ state with approximately seven or
eight layers of nucleated keratinocytes: one layer of bas-
al keratinocytes (the proliferative layer), one or two lay-
ers of suprabasal cells, one or two layers of spinous
cells, and two or three layers of granular cells beneath
the enucleated cells of the cornified layers. Keratinocytes
of the suprabasal, spinous, and granular layers constitute
the differentiating population of epidermal cells. By ap-
proximately 2 weeks of life, epidermal proliferation has
declined and the epidermis has become much thinner,
consisting of the basal layer, one layer of suprabasal
cells, and several enucleated cornified layers, similar to
the adult. We investigated the expression of PAI-2 anti-
gen and mRNA in mouse epidermis during the different
stages of epidermal development using immunohisto-
chemical staining and in situ hybridization, respectively.
In late gestational (Fig. 1A) and early neonatal (Fig.
1C) mouse skin, we detected strong staining for PAI-2
antigen in most suprabasal epidermal layers, but the low-
ermost two or three epidermal layers did not contain de-
tectable PAI-2 antigen. During the first several days of
life, as the epidermis gradually thinned, PAI-2 antigen
became apparent in most of the epidermis, but the basal
cells were still spared (Fig. 1C). By 2 weeks of age, the
entire epidermis, including the basal cells, showed very
intense staining for PAI-2, a pattern which was main-
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tained throughout adulthood (Fig. 1E). At all times, PAI-2
staining was diffuse and cytoplasmic, indicative of an
intracellular localization. In situ hybridization revealed
expression patterns for PAI-2 mRNA that were concor-
dant with the PAI-2 immunohistochemistry. In late ge-
stational epidermis, the signal for PAI-2 mRNA was de-
tected exclusively in suprabasal and spinous keratinocy-
tes (Fig. 1B). Similarly, in neonatal epidermis, most PAI-
2 mRNA was found in immediately suprabasal and spi-
nous layers, although a few basal cells also contained
signal (Fig. 1D). Adult epidermis showed weaker expres-
sion of PAI-2 mRNA, but signal was present in all layers
of the epidermis (Fig. 1F). These results demonstrate
that differentiating epidermal keratinocytes constitutively
express PAI-2; in contrast, basal keratinocytes only ex-
press PAI-2 when the epidermis approaches its adult
morphology, i.e., relatively thin with a low resting prolif-
erative rate.
The majority of epidermal PAI-2 is present
in its 43 kDa, non-glycosylated form
Via western blot analysis, we determined that PAI-2 was
recovered in the low-salt extract of murine epidermis, but
was not detectable in the high-salt/detergent fraction.
These data indicate that epidermal PAI-2 is located most-
ly in the soluble fraction of cellular proteins. The major
band of epidermal PAI-2 had an apparent molecular
weight of 43 kDa (Fig. 2), consistent with previously
published sizes for endogenous (Wohlwend et al. 1987a)
and recombinant (Kawata et al. 1996) non-glycosylated
mouse PAI-2. Interestingly, when lanes were standard-
ized to equivalent amounts of total protein, this 43 kDa
PAI-2 showed an increase in signal intensity in adult
compared to neonatal extracts (Fig. 2A). Neonatal epi-
dermal extracts contained a second band at 105 kDa.
Several other bands for PAI-2 were detectable when
maximal volumes of low-salt extracts were loaded (Fig.
2B). The specificity of these bands was verified by con-
trol immunoblot analysis with normal, non-immune rab-
bit IgG (data not shown). Given that uPA and tPA activi-
ty are detectable in extracts of fetal and neonatal mouse
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Fig. 1A–H Plasminogen activator inhibitor type 2 (PAI-2) expres-
sion patterns change during murine epidermal development. PAI-2
antigen (A, C, E) and mRNA (B, D, F) were localized in mouse
epidermis at day 18 of gestation (A, B), day 5 of life (C, D) and
day 20 of life (E, F). Immunohistochemical staining was per-
formed using polyclonal rabbit anti-mouse PAI-2 IgG, biotinylated
secondary IgG, the avidin–biotin–peroxidase complex, and the
substrate 3,3′-diaminobenzidine. In situ hybridization was per-
formed using [35S]-labeled RNA probe specific for mouse PAI-2.
In control experiments, adult mouse epidermis was incubated with
normal, non-immune rabbit IgG (G NRIgG) or [35S]-labeled sense
probe for PAI-2 mRNA (H). Arrowheadsmark the dermal–epider-
mal junction. PAI-2 antigen and mRNA were expressed in supra-
basal, differentiating keratinocytes of fetal and neonatal epidermis
(A–D). At these ages, basal keratinocytes showed no specific
staining for PAI-2 antigen, and little or no signal for PAI-2 mRNA.
In thin, adult mouse epidermis, PAI-2 antigen and mRNA were
consistently found both in suprabasal and basal keratinocytes (E,
F). The cornified layer showed no consistent staining for PAI-2,
which may be due either to degradation of PAI-2 or to masking of
antigenic determinants upon cross-linking. Bar 40 µm&/fig.c:
epidermis (Jensen and Lavker 1996), we postulate that
these bands may represent complexes of PAI-2 with uPA
or tPA. Such complexes are known to be resistant to SDS
and reducing agents (Wohlwend et al. 1987b). The mole-
cular size of such complexes would be expected within a
range of approximately 80–110 kDa. The intensity of the
105 kDa band was decreased in adult compared to neo-
natal epidermal extracts (Fig. 2A), consistent with the
finding that PA enzyme activity declined considerably
after birth, to barely detectable levels in adult epidermis
(Jensen and Lavker 1996). We also detected PAI-2 bands
at 51, 39, 35, and 33 kDa. The 51 kDa band is consistent
with the published molecular weight for glycosylated
forms of human or mouse PAI-2 (Wohlwend et al. 1987a,
b; Mikus et al. 1993; Kruithof et al. 1995). The low mo-
lecular weight species of 39, 35, and 33 kDa may repres-
ent partially degraded and/or cleaved forms of PAI-2.
Under non-reducing conditions (Fig. 3A), the major PAI-
2 band is a doublet of 43–45 kDa, probably related to
slightly different conformations of the inhibitor.
The majority of epidermal PAI-2 is functionally active
and forms SDS-stable complexes with uPA
Since PAI-2, like other serpins, forms SDS-stable com-
plexes with its target proteinases (Wohlwend et al.
1987b) the presence of active inhibitor can be demon-
strated by a shift in apparent molecular size on SDS-
polyacrylamide gels consequent to incubation with uPA. In
order to assess the functional activity of epidermal PAI-
2, we incubated low-salt extracts of mouse epidermis
with the low molecular weight (33 kDa) form of human
uPA (LMW-uPA) and analyzed the samples by western
blotting. As shown in Fig. 3, most of the 43–45 kDa PAI-
2 band was lost upon incubation with uPA and a 76 kDa
complex band was formed, in good agreement with the
anticipated size for the PAI-2: LMW-uPA complex.
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Fig. 2A, B The majority of epidermal PAI-2 is present in a
43 kDa, non-glycosylated form. Low-salt epidermal extracts were
separated by reducing SDS-PAGE and subjected to western blot
analysis using rabbit anti-mouse PAI-2 IgG, goat anti-rabbit
IgG–horseradish peroxidase, and chemiluminescent detection. A
Western blot analysis of epidermal extracts from mice at days 3, 5,
7, 20 of life and two adults (older than 6 months). All lanes were
loaded with 14 µg total cellular protein. Under reducing condi-
tions, the majority of epidermal PAI-2 was detected as a single 43-
kDa band. The relative amount of this 43 kDa band was increased
in adult compared to neonatal or adolescent epidermis. A second
band (105 kDa) was present in neonatal epidermal extracts. B The
maximal volume (containing 50 µg) total protein of an adult epi-
dermal extract was loaded. Additional bands for PAI-2 were de-
tectable at 105, 78, 51, 39, 35, and 33 kDa. The specificity of
these bands was demonstrated by immunoblotting with normal
rabbit IgG (data not shown). These additional bands may represent
complexed, glycosylated, and/or cleaved forms of PAI-2&/fig.c:
Fig. 3A, B The majority of epidermal PAI-2 is functionally active
and forms SDS-stable complexes with urokinase-type plasminogen
activator (uPA). Adult (>6 months of age) and neonatal (D4 day 4 of
life) low-salt epidermal extracts were incubated in the absence or
presence of the 33 kDa form of human uPA prior to SDS-PAGE.
Western blot analysis was performed using 9.5% SDS-polyacryla-
mide gels and immunodetection with rabbit anti-mouse IgG, as de-
scribed for Fig. 2. Under non-reducing conditions (A), control ex-
tracts of adult and neonatal mouse epidermis contained a doublet for
PAI-2 at 45–43 kDa, which was converted to a band at 76 kDa upon
incubation with uPA. Under reducing conditions (B), there was a
single band detectable for free PAI-2, which complexes with uPA&/fig.c:
Thus, the 43 kDa band represents active inhibitor. In
addition to the appearance of a complex band after incu-
bation with uPA, we also detected a very faint doublet of
42–43 kDa, slightly smaller than the doublet of control
extracts. This slightly smaller doublet may suggest the
presence of a small amount of inactive PAI-2 and/or a
cleaved fraction of total PAI-2.
Epidermal PA inhibitory activity
is mediated at least partially by PAI-2
To quantify epidermal PAI-2 activity at different develop-
mental stages, we titrated the ability of low-salt epidermal
extracts to inhibit uPA-mediated cleavage of the chromo-
genic substrate S-2444. Incubation of standard uPA with
epidermal low-salt extracts led to a concentration-depen-
dent decrease in uPA activity, indicative of the presence
of PA inhibitor(s). When low-salt extracts were standard-
ized to equal amounts of total protein (Fig. 4A), indistin-
guishable levels of PA inhibitory activity were found for
adult and neonatal epidermis. To determine whether this
inhibitory activity was mediated by PAI-2, we performed
immunoprecipitation experiments. Immunoprecipitation
with anti-PAI-2 IgG reduced PA inhibitory activity by ap-
proximately 40%, demonstrating that a significant part of
epidermal PA inhibitory activity was contributed by PAI-2
(Fig. 4B). Increasing the amount of IgG used for immu-
noprecipitation or subjecting the same sample to repeated
immunoprecipitations did not result in further loss of PA
inhibitory activity (data not shown), suggesting that im-
munoprecipitation was complete. Consistent with this in-
terpretation, western blot analysis of low-salt epidermal
extracts which were immunoprecipitated with anti-mouse
PAI-2 revealed no remaining PAI-2 (data not shown).
These data are consistent with the western blots of Fig. 3
in showing active PAI-2 in epidermal extracts. Our inabil-
ity to remove completely uPA inhibitory activity by im-
munoprecipitation with anti-PAI-2 antibody may suggest
the presence of additional PA inhibitor(s) other than PAI-2.
Immunoprecipitation with anti-mouse PAI-1 did not
affect PA inhibitory activity in low-salt epidermal extracts.
PAI-2 is expressed solely in suprabasal
epidermal keratinocytes of the adult mouse footpad
The thickness of trunk epidermis in the mouse greatly de-
creases during neonatal life; however, this is not true for
all epidermal regions of the body. For example, the epi-
dermis of the footpad remains a thick, multi-layered epi-
thelium throughout the life of a mouse. To address wheth-
er adult mouse epidermis invariably expresses PAI-2 both
in suprabasal and basal keratinocytes, or whether this ex-
pression pattern is exclusive to the thin phenotype of
adult mouse epidermis, we localized PAI-2 in footpad
epidermis. Similarly to our results in fetal and neonatal
mouse epidermis, we found intense staining for PAI-2 in
suprabasal epidermal layers of the adult mouse footpad,
but no detectable staining in the basal keratinocytes (Fig.
5A). Accordingly, in situ hybridization revealed signal for
PAI-2 mRNA in the immediately suprabasal and spinous
layers of the footpad but not in the basal keratinocytes or
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Fig. 4A, B Epidermal PA inhibitory activity is mediated at leas
partially by PAI-2. A Low-salt extracts of mouse epidermis were
adjusted to the indicated concentrations of total protein and incu-
bated with standard uPA (25 Plough U/ml) for 1 h at room temper-
ature to allow PAI:uPA complex formation. The chromogenic uPA
substrate S-2444 was then added and uPA activity was assessed by
measuring the increase in optical density at 405 nm (OD 405 nm)
with time. Values shown were obtained after 60 min of incubation
with substrate, a time that was always in the linear range of absorp-
tion. Control wells contained only standard uPA at the same con-
centration (ufA std.). The presence of uPA inhibitors in the extracts
is demonstrated by loss of uPA activity. Epidermal extracts from
mice at day (D) 1, 5, 7, 20 of life and from adult mice had similar
levels of inhibitory activity. B Low-salt extracts of mouse epider-
mis were immunoprecipitated with rabbit anti-mouse PAI-2 IgG or,
as a control, with normal rabbit IgG (NRIgG) prior to the inhibitory
activity assay described in A. The bar labeled Ctrl. shows data of
extracts that were incubated similarly but without addition of anti-
body. Immunoprecipitation of PAI-2 led to loss of PA inhibitory ac-
tivity, as indicated by an increase in uPA activity. Data shown re-
present the average±standard deviation of a total of four experi-
ments with epidermal extracts from mice at day 2, 4, or 20 of life)&/fig.c:
granular cells. The adjacent thin epidermis of the dorsal
foot surface was indistinguishable from trunk epidermis
with respect to morphology and PAI-2 expression in both
basal and suprabasal keratinocytes. Western blot analysis
of low-salt extracts of footpad epidermis demonstrated
the presence of the typical PAI-2 doublet at 45–43 kDa
under non-reducing conditions (Fig. 5B). This band un-
derwent the characteristic size shift to 76 kDa following
incubation with LMW-uPA, indicating that PAI-2 of the
mouse footpad epidermis is functionally active.
PAI-2 is expressed in suprabasal epithelial cells
of stratified squamous epithelia
To determine whether PAI-2 expression is selective for
epidermis, we examined PAI-2 in a number of other mu-
rine epithelial tissues, including stratified squamous epi-
thelia (tongue, oral mucosa, vagina, and esophageal mu-
cosa) and simple epithelia (mucosae of the trachea and
small and large intestine). In the mucosa of the adult
tongue (data not shown), oral cavity, esophagus, and va-
gina (Fig. 6), we found PAI-2 antigen and mRNA pre-
dominantly expressed in suprabasal, differentiating epi-
thelial cells of the spinous and granular layers, resem-
bling the PAI-2 expression pattern in trunk epidermis of
neonatal mice or in the adult footpad epidermis. Basal
epithelial cells did not consistently express PAI-2 mRNA
or antigen, although in esophageal mucosa, focal regions
of basal cells occasionally showed weak expression of
PAI-2 (Fig. 6C, D). The simple epithelia of the small and
large intestine did not show specific expression of PAI-2
antigen or mRNA (data not shown). The pseudostrati-
fied, simple epithelium of the tracheal mucosa showed
faint staining for PAI-2 antigen (Fig. 6I, J), but signal for
PAI-2 mRNA was not detectable (data not shown). Thus,
PAI-2 mRNA was detectable only in stratified squamous
epithelia and not in simple epithelia. The relatively weak
and focal staining in tracheal epithelium indicates a low
level of PAI-2 antigen present in some simple epithelia.
Our findings of low to undetectable levels of PAI-2 in
simple epithelia contrast greatly with the strong and con-
sistent signal for both PAI-2 antigen and mRNA in all
stratified squamous epithelia examined.
Discussion
In the present study, we have demonstrated that mouse
st atified squamous epithelia (epidermis, tongue, esopha-
gus, oral and vaginal mucosa) constitutively and strong-
ly express the proteinase inhibitor PAI-2. In nearly all
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Fig. 5A–C PAI-2 is expressed solely in suprabasal epidermal ke-
ratinocytes of the adult mouse footpad. A Immunohistochemical
staining of adult mouse footpad epidermis. Suprabasal, differenti-
ating keratinocytes of the stratified adult footpad epidermis dis-
played strong staining for PAI-2. B In situ hybridization for PAI-2
mRNA of adult mouse footpad epidermis. PAI-2 mRNA is ex-
pressed in suprabasal keratinocytes of the immediately suprabasal
and spinous layers. Arrowheadsmark the dermal–epidermal junc-
tion. Cross-section of the duct of a sweat land (asterisks); note the
intense staining for PAI-2 in the luminal, ductal epithelial cells. C
Western blot analysis of low-salt epidermal extracts of the adult
foodpad with and without incubation with the 33 kDa human uPA,
as described for Fig. 2. Similarly to extracts of adult trunk epider-
mis (Fig. 2), control extracts revealed the presence of the 45–43
kDa PAI-2 doublet. Incubation with uPA led to a size shift of the
major PAI-2 band to 76 kDa, demonstrating formation of a com-
plex. A faint 43–42 kDa doublet was also detectable after incuba-
tion with uPA. Bar 30 µm&/fig.c:
cases, both antigen and mRNA for PAI-2 are concentrat-
ed in the suprabasal, i.e., differentiating cells of these
multi-layered epithelia. In contrast, simple epithelia such
as trachea and intestine, which comprise only a single
layer of cells residing on a basement membrane, synthe-
size little or no PAI-2. We suggest that expression of
PAI-2 in the differentiating cells of stratified squamous
epithelia indicates a connection of this inhibitor to the
particular properties of terminal differentiation and death
in stratified squamous epithelia.
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Fig. 6A–J PAI-2 antigen and mRNA are expressed in stratified
squamous epithelia. PAI-2 antigen (A, C, E) and mRNA (B, D, F)
were localized in mouse palatal oral mucosa (A, B), esophagus (C,
D) or vagina (E, F). Control experiments were performed using
normal rabbit IgG (G NRIgG) and [35S]-labeled sense probe for
PAI-2 mRNA (H). PAI-2 antigen was weakly detectable in the
simple epithelium of adult mouse trachea (I ) as compared to con-
trol staining with NRIgG (J). Arrowheadsmark the basement
membrane. In all stratified squamous epithelia, expression of PAI-
2 antigen and mRNA was concentrated in the differentiated, supra-
basal epithelial cells. Focal regions of tracheal mucosa showed
weak staining for PAI-2 antigen. Bar 40 µm
One marker of differentiation consistently and
uniquely expressed by stratified squamous epithelia is
transglutaminase 1 (Parenteau et al. 1986; Reibel et al.
1989; Pfundt et al. 1996). This enzyme cross-links pro-
teins to generate the cornified envelope, which is a
unique terminal differentiation product of stratified squa-
mous epithelia, crucial for their barrier function (Green
1977; Rice and Green 1979, Hohl and Roop 1993; Fuji-
moto et al. 1997). PAI-2 contains a putative transgluta-
minase substrate motif and has been shown to be incor-
porated into the cornified envelope of the epidermal ke-
ratinocyte (Jensen et al. 1995, Robinson et al. 1997).
There is evidence from other investigators that PAI-2
cross-linked to trophoblast membranes via the action of
endogenous transglutaminase retains inhibitory activity
(Jensen et al. 1993). Late in terminal differentiation,
when the cornified envelope is forming, the keratinocyte
also proteolytically degrades its organelles via the action
of cellular proteinases. For example, Green (1977) pro-
vided evidence that, at least in cultured human keratino-
cytes, plasminogen is involved specifically in nuclear
disintegration. Hence we speculate that transglutamin-
ase-mediated cross-linking of PAI-2 may concentrate the
inhibitor along the cornified envelope in order to protect
this vital structure from the degradative action of cellular
proteinases.
A second, perhaps related possibility is that PAI-2
may protect the squamous differentiating cells from dy-
ing prematurely. In several cell lines, PAI-2 has been
shown to exert a cytoprotective effect against the induc-
tion of programmed cell death (Kumar and Baglioni
1991, Dickinson et al. 1995, 1998). Recent studies of
mutagenized PAI-2 have shown that a particular interhe-
lical domain is required for this cytoprotective effect; the
same domain has previously been implicated in transglu-
taminase-catalyzed cross-linking of PAI-2 (Jensen et al.
1993, 1994; Dickinson et al. 1998). Simple as well as
stratified epithelial cells undergo a highly specialized
form of programmed cell death (Fesus et al. 1991; Gavrieli
et al. 1992; Hall et al. 1994; Polakowska and Haake
1994; Tamada et al. 1994; Metcalfe and Streuli 1997),
but regulatory mechanisms involved in the initiation,
commitment, and execution of the death pathway may
not be identical among all types of epithelia. One poten-
tially relevant difference imposed by the structural orga-
nization of epithelia concerns their attachment to the
basement membrane, which has been shown in numerous
epithelial cell types to be an important survival signal.
Epithelial cells denied contact with their extracellular
matrix undergo rapid programmed cell death (Frisch and
Francis 1994; Pullan et al. 1996; Metcalfe and Streuli
1997; Rodeck et al. 1997). While simple epithelial cells
remain in contact with the basement membrane through-
out differentiation, stratified squamous epithelial cells
undergo most of their differentiation program after they
have detached from the basement membrane. To accom-
plish their many stages of differentiation and generate a
fully functional cornified envelope, stratified squamous
epithelial cells must remain viable and metabolically ac-
tive for long periods of time after they have detached
from the basement membrane. Hence we speculate that
PAI-2 may be involved in protecting stratified squamous
epithelial cells, which have already lost their attachment
to the extracellular matrix and thus are vulnerable, from
undergoing too rapidly the execution stages of pro-
grammed cell death.
Both of the above hypotheses regarding the role of
PAI-2 in stratified squamous epithelia imply an intracel-
lular site of action. For PAI-2 to be incorporated into the
cornified envelope, it would have to be located inside
the cell, since the cornified envelope is organized on the
intracellular face of the plasma membrane. In the stud-
ies in which PAI-2 was overexpressed in cell lines, pro-
tection from programmed cell death correlated with in-
tracellular PAI-2 (Dickinson et al. 1995,1998). In all
stratified squamous epithelia, our immunohistochemical
staining pattern for PAI-2 suggests a cytoplasmic distri-
bution. The great majority of PAI-2 in stratified squa-
mous epithelia has an apparent molecular weight of 43
kDa, consistent with the non-glycosylated form, which
has been shown to be cell-associated in many cells, in-
cluding monocytes and cultured human keratinocytes
(Wohlwend et al. 1987a, b; Wang and Jensen 1998).
Further analyses revealed that most of the 43 kDa PAI-2
is active. In epidermal extracts we also routinely detect-
ed several minor species of PAI-2 with apparent mole-
cular weights in the range 33–39 kDa. These species
may be related to an approximately 33 kDa form of
PAI-2 found by others (Jensen et al. 1994b) in extracts
of myeloleukemia cells; it has been postulated that this
form is generated in the cytosol and is a biochemical
marker for apoptosis. Since PAI-2 is a member of the
large family of serpins, most of which are found in the
circulation, the postulation of an intracellular role was
initially suprising. However, PAI-2 is an ovalbumin-type
serpin (ov-serpin), with structural and sequence homol-
ogy to serpins such as skin-derived anti-leukoproteinase
(SKALP), proteinase inhibitor 6, maspin, squamous cell
carcinoma antigen (SCCA), and the viral serpin crmA
(Kruithof et al. 1995). Ov-serpins lack a classical signal
s quence and are therefore expressed mainly in the cy-
tosol; in some cases, secretion is facilitated by glycosy-
lation of the inhibitor molecule. Recent studies have lo-
calized SKALP, proteinase inhibitor 6, and SCCA to the
more differentiated keratinocytes of various types of
stratified squamous epithelia (Pfundt et al. 1996; Scott
et al. 1996; Schick et al. 1997). In the case of proteinase
inhibitor 6, expression was found to be exclusively in-
tracellular, suggesting yet unknown intracellular func-
tion(s) of this serpin. Furthermore, as an inhibitor of the
i tracellular caspase interleukin-1β-converting enzyme
(ICE), the viral serpin crmA is the first serpin shown to
have a defined intracellular target (Komiyama et al.
1996).
Although several lines of evidence point to an intra-
cellular role for PAI-2, we recognize that an alternative,
r additional, extracellular role for PAI-2 involves inhibi-
tion of uPA or tPA. Both of these plasminogen activators
are present in normal mouse epidermis (Jensen and
Lavker 1996). Although their epidermal functions re-
main undefined, we have previously presented evidence
 uPA may promote epidermal proliferation (Jensen
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and Lavker 1996). Interestingly, of all the murine strati-
fied squamous epithelia that we examined, adult epider-
mis of the ‘thin’ phenotype was the only one in which
PAI-2 was found in the basal (i.e., proliferative) layer.
This may suggest that, at least under certain conditions,
PAI-2 may serve additional functions in basal keratino-
cytes, e.g., regulation of uPA activity.
Finally, it is possible that PAI-2 may provide a pro-
tective mechanism against microbial infection through
stratified squamous epithelia. Although intact epithelia
constitute a formidable barrier against microbial inva-
sion, breaks within tissues can allow entry of foreign or-
ganisms. Several invasive bacteria express endogenous
plasminogen activators and bind plasminogen, which
they may use to penetrate the extracellular matrix
(Boyle and Lottenberg 1997; Korhonen et al. 1997).
Perhaps disruption of the stratified squamous epitheli-
um, with the resulting death of keratinocytes, releases
their large store of intracellular PAI-2 into the extracel-
lular space, there to inhibit any bacterial-mediated plas-
minogen activation and thus limit the invasive capacity
of the infectious agent.
In sum, we believe that the selective presence of PAI-2
in the differentiated cells of stratified squamous epithelia
suggests several possible roles related to the protective
barrier functions of this class of epithelia. Future investi-
gations are required to determine the nature and the tar-
get of PAI-2 actions.
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